Neurológia pre prax 5/2017
Challenges of ciclosporin and azathioprin dosage for myasthenia gravis
Azathioprin (Imuran) and ciclosporin (Sandimmun Neoral, Equoral) are among the most widely used immunosuppressive drugs for myasthenia gravis. They are very efficient and help to improve patient’s quality of life. However, such therapy has some risks. At least part of the risks can be avoided by managing the right dose, which requires certain experience. The aim of this article is a review of their side effects, metabolic pathways and interactions, therapeutic drug monitoring and some dosage recommendations.
Keywords: azathioprin, ciclosporin, cyclosporin, neoral, therapeutic drug monitoring
